An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors

Proteasome inhibitors bortezomib, carfilzomib and ixazomib (approved by the US Food and Drug Administration [FDA]) induce remissions in patients with multiple myeloma (MM), but most patients eventually become resistant. MM and other hematologic malignancies express ubiquitous constitutive proteasome...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Downey-Kopyscinski, Sondra, Daily, Ellen W., Gautier, Marc, Bhatt, Ananta, Florea, Bogdan I., Mitsiades, Constantine S., Richardson, Paul G., Driessen, Christoph, Overkleeft, Herman S., Kisselev, Alexei F.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6177641/
https://ncbi.nlm.nih.gov/pubmed/30266819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016360
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados